Study of Potential Blocking Peptides Targeting the SARS-CoV-2 RBD/hACE2 Interaction.

ABSTRACT:

Background/objectives

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, was declared a public health emergency in early 2020. The infection initiates when the receptor-binding domain (RBD) of the viral spike protein binds to human angiotensin-converting enzyme 2 (ACE2). Despite the success of vaccination efforts, the emergence of new variants highlights the ongoing need for treatments targeting these evolving strains. In silico methods previously identified peptides BP2, BP9, and BP11 as being capable of disrupting the RBD-ACE2 interaction, though their efficacy has not been experimentally validated until now.

Methods

In this study, these peptides were recombinantly produced in the yeast Komagataella phaffii, and the activi

SUBMITTER: Villada-Troncoso SM 

PROVIDER: S-EPMC11435355 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature